| Online-Ressource |
Verfasst von: | Klein, Katrin [VerfasserIn]  |
| Süsal, Caner [VerfasserIn]  |
| Schäfer, Sebastian Markus [VerfasserIn]  |
| Becker, Luis Eduardo [VerfasserIn]  |
| Beimler, Jörg [VerfasserIn]  |
| Schwenger, Vedat [VerfasserIn]  |
| Zeier, Martin [VerfasserIn]  |
| Schemmer, Peter [VerfasserIn]  |
| Macher-Göppinger, Stephan [VerfasserIn]  |
| Scherer, Sabine [VerfasserIn]  |
| Opelz, Gerhard [VerfasserIn]  |
| Morath, Christian [VerfasserIn]  |
Titel: | Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis |
Verf.angabe: | Katrin Klein, Caner Süsal, Sebastian M. Schäfer, Luis Eduardo Becker, Jörg Beimler, Vedat Schwenger, Martin Zeier, Peter Schemmer, Stephan Macher-Goeppinger, Sabine Scherer, Gerhard Opelz, Christian Morath |
E-Jahr: | 2013 |
Jahr: | 26 January 2013 |
Umfang: | 4 S. |
Fussnoten: | Gesehen am 08.06.2022 |
Titel Quelle: | Enthalten in: Atherosclerosis. Supplements |
Ort Quelle: | Amsterdam [u.a.] : Elsevier Science, 2000 |
Jahr Quelle: | 2013 |
Band/Heft Quelle: | 14(2013), 1, Seite 199-202 |
ISSN Quelle: | 1878-5050 |
Abstract: | Objective - Due to increasing waiting times for deceased donor kidneys, living donor kidney transplantation is increasingly performed in the presence of donor-specific antibodies (DSA). - Methods - Twenty-three patients with Luminex-detected DSA were successfully desensitized by anti-CD20 therapy and immunoadsorption (N = 19) or plasmapheresis (N = 4) and received a kidney transplant from a living donor. Twelve of the 23 patients (52%) had a positive CDC and/or ELISA crossmatch result before desensitization. Six patients were negative in CDC as well as ELISA screening but positive in Luminex for DSA. - Results - The 23 patients received a median of 8 apheresis treatments before and 5 treatments after transplantation. Induction therapy was performed with either thymoglobulin (N = 11) or basiliximab (N = 12). The 2-year graft survival rate was 100%. At last follow up, a median of 12 months after transplantation, median serum creatinine was 1.42 mg/dL, median MDRD-GFR 59.5 mL/min/1.73 m2, and median urinary protein-to-creatinine ratio 0.12. Ten out of fourteen patients (71%) who had completed the first year after transplantation by the time of analysis had no DSA by day 360. Acute T-cell mediated rejection was diagnosed in one patient (4%), and antibody-mediated changes were found in 5 patients (22%). Four out of these 5 patients showed evidence of persistent (N = 2) or reemerging plus/minus de novo DSA (N = 2) on day 360, and the 2 patients with persistent DSA lost their allograft subsequently on days 750 and 810, respectively. Infectious complications were infrequent. - Conclusions - Our previously described treatment algorithm for desensitization of living donor kidney transplant recipients with DSA results in good graft outcomes with a low rate of side effects. |
DOI: | doi:10.1016/j.atherosclerosissup.2012.10.030 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext: https://doi.org/10.1016/j.atherosclerosissup.2012.10.030 |
| Volltext: https://www.sciencedirect.com/science/article/pii/S1567568812000414 |
| DOI: https://doi.org/10.1016/j.atherosclerosissup.2012.10.030 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | Desensitization |
| Donor-specific antibodies |
| Immunoadsorption |
| Kidney transplantation |
| Living donation |
| Rituximab |
K10plus-PPN: | 1751707121 |
Verknüpfungen: | → Zeitschrift |
Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis / Klein, Katrin [VerfasserIn]; 26 January 2013 (Online-Ressource)